Cannabinoids and B cells: emerging targets for treating progressive multiple sclerosis

Mult Scler. 2011 Mar;17(3):259-61. doi: 10.1177/1352458511399799.
No abstract available

Publication types

  • Comment
  • Editorial
  • Introductory Journal Article

MeSH terms

  • Animals
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / immunology
  • Chemokine CXCL13 / cerebrospinal fluid
  • Disability Evaluation
  • Humans
  • Immunoglobulin M / biosynthesis
  • Immunologic Factors / therapeutic use*
  • Multiple Sclerosis, Chronic Progressive / diagnosis
  • Multiple Sclerosis, Chronic Progressive / drug therapy*
  • Multiple Sclerosis, Chronic Progressive / genetics
  • Multiple Sclerosis, Chronic Progressive / immunology
  • Multiple Sclerosis, Relapsing-Remitting / diagnosis
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / genetics
  • Multiple Sclerosis, Relapsing-Remitting / immunology
  • Oligoclonal Bands / cerebrospinal fluid
  • Polymorphism, Genetic
  • Prognosis
  • Receptor, Cannabinoid, CB1 / agonists*
  • Receptor, Cannabinoid, CB1 / genetics
  • Severity of Illness Index

Substances

  • CXCL13 protein, human
  • Chemokine CXCL13
  • Immunoglobulin M
  • Immunologic Factors
  • Oligoclonal Bands
  • Receptor, Cannabinoid, CB1